Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease and respiratory. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 The report on the Global ... the concerned market for revenue forecasts and market trends. ... of 51.9% from 2013 to 2018. At the projected ... of $1,415.6 million by 2018. , Browse through the ... for information about the market segmentation and in-depth analysis ...
(Date:11/26/2014)... 2014 In keeping with the holiday ... bevy of last-minute Thanksgiving savings. The company is offering ... all product lines this holiday weekend as well as ... Friday, and Cyber Monday are right around the corner, ... both loyal customers and those looking to explore their ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... results from a survey of European physicians at ... on Innovation and Biological Therapies" at the Spanish ... event, hosted by EuropaBio and the Spanish Bioindustry ... of Health, physicians from Spanish oncology and rheumatology ...
(Date:11/26/2014)... PMG Research, Inc. announced today ... a network of sites that provide clinical research services to ... patient lives through its partnerships with large physician practices and ... site locations in the Southeastern United States and spans over ... board will be held by: Dr. Robert Holmes, ...
Breaking Biology Technology:Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3ASBM Presents European Physicians Survey at Spanish Ministry of Health 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3
... , , , ... of hospital-related infections in the U.S. costs up to $11 billion a ... implanted in patients. Until now, efforts to control drug-resistant biofilms on such ... mats developed by collaborators Pat Mather and Dacheng Ren of the Syracuse ...
... ... announced the PX14400 high-speed digitizer, the industry,s most advanced wideband and high dynamic ... when using the programmable gain amplifier in 1 dB steps for maximum gain ... is employed for the cleanest possible signal path to the ADC. 1 GB ...
... /PRNewswire/ - Enerkem, a leading waste-to-biofuels and green chemicals ... by its partners, the City of Edmonton and the ... on their joint advanced energy research facility. The ceremony ... Advanced Education and Technology in Alberta, and the Edmonton ...
Cached Biology Technology:New Antimicrobial Webs Sterilize Medical Implants for 14 Days 2Signatec Unveils PX14400, Its High-Speed PCI-Express Digitizer Capable of Sustained Recordings Over 1.2 GB/s with Xilinx Virtex-5 FPGAs for Embedded Real-Time Processing 2Signatec Unveils PX14400, Its High-Speed PCI-Express Digitizer Capable of Sustained Recordings Over 1.2 GB/s with Xilinx Virtex-5 FPGAs for Embedded Real-Time Processing 3Signatec Unveils PX14400, Its High-Speed PCI-Express Digitizer Capable of Sustained Recordings Over 1.2 GB/s with Xilinx Virtex-5 FPGAs for Embedded Real-Time Processing 4Enerkem Announces Construction Start on Advanced Energy Research Facility in Edmonton, Alberta 2Enerkem Announces Construction Start on Advanced Energy Research Facility in Edmonton, Alberta 3
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
(Date:11/7/2014)... Calif. , Nov. 7, 2014  In conjunction with ... Police Departments, The Community Foundation of the Verdugos ... DNA JUSTICE PROJECT," a $250,000 initiative to keep ... initial phase. In its first six months of existence, the ... needed evidence support for local law enforcement. "Because ...
(Date:11/6/2014)... is an asset for a predator. Except when that predator ... tiger beetle, relative to its size, is the fastest creature ... body lengths per second (at about five miles per hour). ... take the sprinting gold from the tiger beetle, a person ... The tiger beetle has a problem. At peak speeds, everything ...
Breaking Biology News(10 mins):Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2The tiger beetle: Too fast to see 2
... YORK, Feb. 17, 2011 A research group led by ... genetic variant that allows a fish in the Hudson River ... study published in the February 18, 2011, online issue of ... River fish apparently evolved rapidly in response to the toxic ...
... work. Researchers at Rochester Institute of Technology are ... is doubly "green" because algae consume nitrates and phosphates ... end result: clean wastewater and stock for a promising ... into receiving bodies of water at treatment plants, while ...
... research could eventually lead to new approaches for controlling ... which are caused by trypanosomes carried by the bloodsucking ... reproduction evolved very early and is now ubiquitous in ... living organisms except bacteria). However, real evidence is ...
Cached Biology News:A genetic mutation allows Hudson River fish to adapt to PCBs 2The green machine: Algae clean wastewater, convert to biodiesel 2Shining a light on trypanosome reproduction 2
... paper sandwiches are composed of a precut ... thick filter paper that are preassembled into ... These 7 x 8.5 cm membrane sandwiches ... Gel-sized gels and are supplied as a ...
... This kit is designed to knockout or alter ... less than one week. Red/ET recombination allows the ... precise, specific, and faithful manner. An FRT-flanked kanamycin ... which can be used to replace a gene ...
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... LIGHT. Useful in cell activation experiments when calcium dose-response ... Soluble in DMSO or EtOH. For use ... in DMSO is recommended. Microliter amounts of this solution ... mixing (e.g. 10 μl into 5 ml of H ...
Biology Products: